Anixa is focused on the treatment, prevention, and diagnosis of cancer and infectious diseases.

Anixa Biosciences, Inc. is developing therapeutic and diagnostic programs that are focused on critical unmet needs in oncology and infectious disease. Anixa’s oncology programs are using the body’s immune system to take multiple approaches in fighting cancer—developing treatments, vaccines, and diagnostics. Anixa’s infectious disease program consists of a treatment for COVID-19 focused on inhibiting certain protein function necessary for viral replication.



We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.

Breast Cancer Vaccine

We are developing a revolutionary breast cancer vaccine technology focused on treating as well as preventing triple negative breast cancer (TNBC), the most lethal form of the disease.


We are developing a treatment for COVID-19 that is designed to inhibit protein function necessary for replication of SARS-CoV-2, the virus causing the disease.


We are developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body’s immune response to the presence of a malignancy.

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

Anixa Biosciences and OntoChem Have Synthesized Four Potential Covid-19 Drugs for Testing in Biological Assays


Anixa Biosciences and OntoChem Announce Discovery of First Covid-19 Therapeutic Candidate


Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Biomarker Insights Highlighting Cchek™ Liquid Biopsy Technology


Stock Data

View Investors Relations
Nasdaq: ANIX